MDCM

Benitec Biopharma to Host Virtual R&D Day to Discuss BB-301 Clinical Program in Oculopharyngeal Muscular Dystrophy on April 18, 2024

Retrieved on: 
Tuesday, April 9, 2024
Neurology, University college, Patient, McGill University Health Centre, Head, Doctor of Philosophy, MDCM, OPMD, Otorhinolaryngology, Natural history

To register, click here .

Key Points: 
  • To register, click here .
  • The event will feature two key opinion leaders who will discuss the clinical symptoms and the natural history of oculopharyngeal muscular dystrophy (OPMD), a rare genetic muscle disorder.
  • The key opinion leaders will also review the clinical and radiographic methods employed to evaluate disease progression and discuss the current treatment landscape for patients diagnosed with OPMD.
  • A live question and answer session will follow the formal presentations.

Fast, Faster, Fastest: Is It Time for Automated Model Building? Upcoming Webinar Hosted by Xtalks

Retrieved on: 
Monday, October 16, 2023
Doctor of Philosophy, Python, Microsoft Excel, Automation, Thermo Fisher Scientific, Communication, MDCM, FACP, National Institute for Health and Care Excellence, PPD, EDT, HTA, NICE, DICE, FRCPC, Management, Medical device

TORONTO, Oct. 16, 2023 /PRNewswire-PRWeb/ -- Health economic models are now used in every stage of product development, from early planning and portfolio selection based on target product profiles; through analyses to understand which gaps in the evidence have the biggest impact on predicted value; to health technology assessment (HTA) submissions, budget impact estimates and price negotiations. To facilitate quicker development of models, whole disease models that can be reused have been proposed. The National Institute for Health and Care Excellence (NICE) in the UK is piloting the pathway assessment framework where HTA will be supported by an open-source model available to all stakeholders. This will also help ensure consistency across decisions that previously were hard to consolidate across single technology appraisals.

Key Points: 
  • The featured speakers will discuss how automation tools can leverage the power of server-based installations while preserving the Excel-based nature of models preferred by stakeholders.
  • To facilitate quicker development of models, whole disease models that can be reused have been proposed.
  • This will also help ensure consistency across decisions that previously were hard to consolidate across single technology appraisals.
  • Remaining challenges regarding training of model builders and users, and making such models submission ready will be discussed by the panelists.

Notice of Compliance issued regarding Rezurock(TM) (belumosudil tablets)

Retrieved on: 
Tuesday, March 21, 2023
Faculty, GVHD, Mouth, MDCM, Eye, Quality of life, Esophagus, Inflammation, Lung, Harvard Medical School, Dana–Farber Cancer Institute, Fibrosis, Assistant professor, Medical director, MD, Patient, Division, Outline of health sciences, Disease, McGill University, Liver, FRCPC, Health, MPH, Health Canada, McGill University Faculty of Medicine and Health Sciences, Skin, Pharmaceutical industry, Dentistry, Hematology, Sanofi, Medicine

This includes fibrosis, which can have a devastating impact on a patient's health and well-being.

Key Points: 
  • This includes fibrosis, which can have a devastating impact on a patient's health and well-being.
  • I welcome the approval of Rezurock™ in Canada because it brings a new treatment option to patients who are experiencing severe and life-threatening symptoms."
  • It was developed specifically for the treatment of chronic graft-versus-host disease and it has anti-fibrotic properties.
  • The availability of Rezurock™ represents an advancement for patients who have undergone a stem cell transplant and require treatment for chronic graft-versus-host disease."

Worldwide Medical Device Contract Manufacturing Industry to 2028 - Featuring 3D Systems, Accenture PLC and Affinity Biologicals Among Others - ResearchAndMarkets.com

Retrieved on: 
Tuesday, February 1, 2022
Health, Other Manufacturing, Manufacturing, Medical Devices, OEM, Pressure, Growth, Industry, Adoption of electronic medical records in U.S. hospitals, CAGR, Electronic, MDCM, Solution, Geography, Original equipment manufacturer, Risk management, Medical device

As estimated, the medical device contract manufacturing global market is expected to grow at a mid single digit CAGR to reach $82,035.6 million by 2028.

Key Points: 
  • As estimated, the medical device contract manufacturing global market is expected to grow at a mid single digit CAGR to reach $82,035.6 million by 2028.
  • Medical device contract manufacturing is a business model in which a medical device company or Original Equipment Manufacturer (OEM) outsources certain or the whole production activities of their whole medical device or certain components of the device to another company with specialized knowledge, technical expertise and efficient business operations.
  • The medical device contract manufacturing global market is categorized into various market segments based on the device type, services offered, product type, application and geography.
  • Based on the device type, the market is bifurcated into Electronic Medical Device Contract Manufacturing and Non-Electronic Medical Device Contract Manufacturing.